As previously reported, Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $142, up from $115. With a broad, strategic suite of programs, the firm views BioNTech as “being at the nexus of significant developments occurring in the oncology field” and uniquely positioned to develop novel-novel combination approaches to transform cancer care, the analyst tells investors. Data unlocks in 2026 could position the company with “a leading foothold in an emerging wave of new product cycles,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech Outlines 2026 Strategy and Milestones at J.P. Morgan Healthcare Conference
- BioNTech: Stable COVID-19 Vaccine Base and Catalyst-Rich Oncology Pipeline Support Buy Rating
- BioNTech outlines 2026 areas of focus
- BioNTech Maps Out Catalyst-Rich 2026 Oncology Agenda at J.P. Morgan Healthcare Conference
- BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial